Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.
CONCLUSION: The treatment sequences including ABA as the second biologic option appear more cost-effective than those including RTX in a patients with moderate to severe RA and an insufficient response to a first anti-TNF agent.
PMID: 22582103 [PubMed]
Source: Open Rheumatology Journal - Category: Rheumatology Tags: Open Rheumatol J Source Type: research
More News: Abatacept | Arthritis | Enbrel | Humira | Orencia | Remicade | Rheumatoid Arthritis | Rheumatology | Rituxan